Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-cef8236d2ba001c606577d8a44188d3e"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-cef8236d2ba001c606577d8a44188d3e"/>
<resource>
<Composition>
<id value="composition-en-cef8236d2ba001c606577d8a44188d3e"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-cef8236d2ba001c606577d8a44188d3e"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-cef8236d2ba001c606577d8a44188d3e</b></p><a name="composition-en-cef8236d2ba001c606577d8a44188d3e"> </a><a name="hccomposition-en-cef8236d2ba001c606577d8a44188d3e"> </a><a name="composition-en-cef8236d2ba001c606577d8a44188d3e-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/09/511/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - conbriza</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/09/511/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpcef8236d2ba001c606577d8a44188d3e"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - conbriza"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet:</p><ol type="1"><li>What CONBRIZA is and what it is used for</li><li>What you need to know before you take CONBRIZA</li><li>How to take CONBRIZA</li><li>Possible side effects</li><li>How to store CONBRIZA</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What conbriza is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What conbriza is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>CONBRIZA contains the active substance bazedoxifene, and is a medicine that belongs to a group of non-hormonal medicines called Selective Oestrogen Receptor Modulators (SERMs). It is used for the treatment of osteoporosis in women after they have reached menopause, when they are at an increased risk of fractures. It works by slowing or stopping the thinning of bone in these women. This medicine should not be used for the treatment of osteoporosis in men.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take conbriza"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take conbriza"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take CONBRIZA</p><p>if you are allergic to bazedoxifene or any of the other ingredients of this medicine (listed in section 6).</p><p>if you have or have had a blood clot (for example, in the blood vessels in your legs, lungs, or eyes).</p><p>if you are pregnant or could still become pregnant. This medicine may cause harm to your unborn child if taken during pregnancy.</p><p>if you have any unexplained vaginal bleeding. This must be investigated by your doctor.</p><p>if you have active uterine cancer.</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking CONBRIZA</p><p>as it may increase your risk of getting blood clots. While very infrequent, these clots can cause serious medical problems, disability or death. Speak with your doctor to see if you are at increased risk for blood clots.</p><p>if you are immobile (unable to move) for some time, such as being wheel-chair bound, sitting for a prolonged period of time or having to stay in bed while recovering from an operation or illness. If you are traveling on long trips, you should walk around or exercise your legs and feet at regular intervals. This is because sitting for a long time in the same position may prevent good blood circulation and may increase your risk of blood clots. If you need to remain immobile for an extended period of time or are scheduled to have surgery, it is important for you to talk to your doctor about ways you can reduce the risk of blood clots.</p><p>if you are pre-menopausal. CONBRIZA has only been studied in women who have reached menopause, and therefore is not recommended.</p><p>if you have had increased levels of triglycerides (a type of fat found in your blood) in the past.</p><p>if you have liver or severe kidney problems.</p><p>if you have any vaginal bleeding while you take CONBRIZA, you should speak with your doctor.</p><p>if you are suffering from breast cancer, as there is insufficient experience with this medicine use in women with this disease.</p><p>The above are some reasons why this medicine may not be suitable for you. If any of them apply to you, talk to your doctor before you take the medicine.</p><p>Other medicines and CONBRIZA</p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.</p><p>Pregnancy and breast-feeding</p><p>CONBRIZA is for use only by postmenopausal women. It must not be taken by women who are pregnant or who could still have a baby. Do not take this medicine if you are breast-feeding, because it is not known whether it is excreted in mother's milk.</p><p>Driving and using machines</p><p>If you feel drowsy after taking this medicine, you should avoid driving or operating machines.</p><p>You may notice problems with your eyesight such as blurred vision while taking this medicine. If this happens, you should avoid driving or operating machines until your doctor tells you that it is safe to do so.</p><p>CONBRIZA contains lactose and sodium</p><p>This medicine contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take conbriza"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take conbriza"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. You should continue taking this medicine as long as your doctor tells you to. In order for this medicine to treat osteoporosis, it must be taken daily.</p><p>The recommended dose is one tablet by mouth daily. Taking more than one tablet daily is not more effective and may carry additional risks.</p><p>You can take the tablet at any time of the day, with or without food.</p><p>This medicine should be taken with an adequate amount of calcium and vitamin D. Consult your doctor to see if your dietary calcium and vitamin D intake is adequate and whether you need calcium and vitamin D supplementation. If you take supplemental calcium and/or vitamin D, it may be taken at the same time as this medicine.</p><p>If you take more CONBRIZA than you should</p><p>Tell your doctor or pharmacist if you accidentally take more CONBRIZA than you should.</p><p>If you forget to take CONBRIZA</p><p>If you forget to take a tablet, take it as soon as you remember. However, if it is almost time to take your next dose of this medicine, skip the dose you missed and only take your next scheduled dose. Do not take a double dose to make up for a forgotten tablet.</p><p>If you stop taking CONBRIZA</p><p>If you decide to stop taking this medicine before finishing the prescribed course of treatment, you should talk to your doctor first.</p><p>If you have any further questions on the use or stopping the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects Stop taking CONBRIZA and see a doctor immediately</p><p>Uncommon (may affect up to 1 in 100 people):</p><p>If you have signs of a blood clot in the legs or lungs, such as painful swelling and redness of the legs, sudden chest pain, or difficulty in breathing;</p><p>If you have signs of a blood clot in the eye (retinal vein), such as one sided visual disturbance or visual impairment or blurring or loss of vision in one eye.</p><p>If you get any of the problems listed under Do not take CONBRIZA</p><p>Not known (frequency cannot be estimated from the available data): If you have other events affecting the eye and/or vision (seeing sparks or flashes of light, narrowing of visual field, and swelling of eye or eyelid)</p><p>Other side effects</p><p>Some patients have experienced the following side effects while taking CONBRIZA:</p><p>Very common (may affect more than 1 in 10 people):</p><p>Muscle spasms (includes leg cramps)</p><p>Hot flushes</p><p>Swelling of the hands, feet and legs (peripheral oedema)</p><p>Common (may affect up to 1 in 10 people):</p><p>Allergic reaction (including hypersensitivity and urticaria)</p><p>Rash, itching</p><p>Dry mouth</p><p>Increase in blood triglycerides (fat found in your blood)</p><p>Increase in liver enzymes</p><p>Drowsiness</p><p>Not known (frequency cannot be estimated from the available data):</p><p>Palpitations (awareness of your heart beat)</p><p>Dry eye, eye pain, visual acuity reduced, visual impairment, blepharospasm (abnormal, involuntary blinking or spasm of the eyelids). Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store conbriza"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store conbriza"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last date of that month. Do not store above 25 C. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What CONBRIZA contains</p><p>The active substance is bazedoxifene. Each film-coated tablet contains bazedoxifene acetate equivalent to 20 mg bazedoxifene.</p><p>The other ingredients are lactose monohydrate, microcrystalline cellulose, pregelatinised starch (maize), sodium starch glycolate, sodium lauryl sulfate, colloidal anhydrous silica, magnesium stearate, ascorbic acid, hypromellose, titanium dioxide (E171) and macrogol 400 (see section 2 CONBRIZA contains lactose and sodium ). What CONBRIZA looks like and contents of the pack CONBRIZA is supplied as a white to off-white, capsule-shaped, film-coated tablet marked with WY20 . The tablet is approximately 1.5 cm in length. They are packed in PVC/Aclar blisters and are available in packs of 7, 28, 30, 84 or 90 tablets. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder<br/>Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium. Manufacturer<br/>Pfizer Ireland Pharmaceuticals, Little Connell, Newbridge, County Kildare, Ireland. For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Luxembourg/Luxemburg Pfizer NV/SA T l/Tel: +32 (0)2 554 62 Latvij<br/>Pfizer Luxembourg SARL fili le Latvij<br/>Tel: +371 670 35<br/>,</p><p>.: +359 2 970 4Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel: +370 52 51 4 esk republika Pfizer, spol. s r.o.<br/>Tel: +420-283-004-Magyarorsz g Pfizer Kft Tel.: +36 1 488 3Danmark Pfizer ApS<br/>Tlf: +45 44 20 11 Malta Vivian Corporation Ltd. Tel: +356 21344Deutschland PFIZER PHARMA GmbH Tel: +49 (0)30 550055-51Nederland Pfizer BV Tel: +31 (0)10 406 43 Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7Norge Pfizer AS Tlf: +47 67 526<br/>Pfizer A.E. : +30 210 6785 sterreich Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0</p><p>Espa a Pfizer, S.L. Tel: +34 91 490 99 Polska Pfizer Polska Sp. z o.o.<br/>Tel.: +48 22 335 61 France Pfizer<br/>T l: +33 (0)1 58 07 34 Portugal Laborat rios Pfizer, Lda. Tel: +351 21 423 5Hrvatska Pfizer Croatia d.o.o. Tel: +385 1 3908 Rom nia Pfizer Romania S.R.L Tel: +40 (0) 21 207 28 Ireland Pfizer Healthcare Ireland Tel: 1800 633 363 (toll free) +44 (0)1304 616Slovenija Pfizer Luxembourg SARL Pfizer, podru nica za svetovanje s podro ja farmacevtske dejavnosti, Ljubljana Tel: +386 (0)1 52 11 sland Icepharma hf. S mi: +354 540 8Slovensk republika Pfizer Luxembourg SARL,<br/>organiza n zlo ka<br/>Tel: +421 2 3355 5Italia Pfizer S.r.l.<br/>Tel: +39 06 33 18 Suomi/Finland Pfizer Oy<br/>Puh/Tel: +358 (0)9 430 K<br/>Pfizer . . (Cyprus Branch) : +357 22 817Sverige<br/>Pfizer AB<br/>Tel: +46 (0)8 550 520 United Kingdom (Northern Ireland) Pfizer Limited Tel: +44 (0) 1304 616This leaflet was last revised in {MM/YYYY}. Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site: <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu/</a>.</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpcef8236d2ba001c606577d8a44188d3e"/>
<resource>
<MedicinalProductDefinition>
<id value="mpcef8236d2ba001c606577d8a44188d3e"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpcef8236d2ba001c606577d8a44188d3e"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpcef8236d2ba001c606577d8a44188d3e</b></p><a name="mpcef8236d2ba001c606577d8a44188d3e"> </a><a name="hcmpcef8236d2ba001c606577d8a44188d3e"> </a><a name="mpcef8236d2ba001c606577d8a44188d3e-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/09/511/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: CONBRIZA 20 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/09/511/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="CONBRIZA 20 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
